Evidence map›Paper›PMID 29802810›Full record

ArticleBJU international2019

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.

Elizabeth K Bancroft, Sibel Saya, Elizabeth C Page, Kathryn Myhill, Sarah Thomas, Jennifer Pope, Anthony Chamberlain, Rachel Hart, Wayne Glover, Jackie Cook and 19 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in BJU international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00261456 (The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00261456 active not recruitingnot on this map

The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer: Targeted Screening in Men at Higher Genetic Risk and Controls

TypeobservationalSponsorInstitute of Cancer Research, United KingdomRan2005 to 2030Enrolled3,500ConditionsProstate Cancer, BRCA Mutation, Mismatch Repair Gene Mutation, Genetic Predisposition to DiseaseArmsPSA test, Prostate Biopsy
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 17 institutions in 6 countries.

Elizabeth K BancroftOncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.ORCID 0000-0002-5482-5660
Sibel SayaOncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
Elizabeth C PageOncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
Kathryn MyhillOncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
Sarah ThomasOncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
Jennifer PopeOncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
Anthony ChamberlainOncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
Rachel HartClinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK.
Wayne GloverClinical Genetics Unit, Birmingham Women's Hospital, Birmingham, UK.
Jackie CookSheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK.
Derek J RosarioDepartment of Urology, Royal Hallamshire Hospital, Sheffield, UK.
Brian T HelfandJohn and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.
Christina Hutten SelkirkJohn and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.
Rosemarie DavidsonClinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, UK.
Mark LongmuirClinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, UK.
Diana M EcclesWessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
Neus GadeaHigh Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona, Spain.
Carole BrewerClinical Genetics Department, Royal Devon and Exeter Hospital, Exeter, UK.
Julian BarwellDepartment of Genetics, University of Leicester, Leicester, UK.
Monica SalinasHereditary Cancer Programme, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain.
Lynn GreenhalghCheshire and Mersey Clinical Genetics Service, Liverpool Women's Hospital, Liverpool, UK.
Marc TischkowitzAcademic Department of Medical Genetics, University of Cambridge, Cambridge, UK.
Alex HendersonNorthern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle, UK.
David Gareth EvansManchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Saundra S BuysHuntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.
IMPACT Study Steering Committee
IMPACT Collaborators
Rosalind A EelesOncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
Neil K AaronsonDivision of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Royal Marsden NHS Foundation Trust · GBBirmingham Women's Hospital · GBNorthShore University HealthSystem · USQueen Elizabeth University Hospital · GBHebron University · PSInstitut d'Investigació Biomédica de Bellvitge · ESNewcastle upon Tyne Hospital · GBPrincess Anne Hospital · GBRoyal Devon and Exeter Hospital · GBRoyal Hallamshire Hospital · GBSheffield Children's Hospital · GBThe Netherlands Cancer Institute · NLUniversity of Cambridge · GBUniversity of Leicester · GBUniversity of Liverpool · GBUniversity of Manchester · GBUniversity of Utah · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Cancer Research UK 12518Cancer Research UK 13232Cancer Research UK 15007Cancer Research UK 17528Cancer Research UK 21332Cancer Research UK C5047/A13232Cancer Research UK C5047/A17528Cancer Research UK C5047/A21332Department of Health RP-PG-0707-10031NCATS NIH HHS UL1 TR002538NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectivesTo report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND

methodsMen enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented.

resultsA total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status.

conclusionThis is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening.

Indexed as

Genes, BRCA1Genes, BRCA2AdultAnxietyCase-Control StudiesDepressionEarly Detection of CancerHealth Knowledge, Attitudes, PracticeHumansLongitudinal StudiesMaleMiddle AgedMutationPerceptionProstatic NeoplasmsPsychiatric Status Rating ScalesBRCA1BRCA2#pcsm#ProstateCancerpsychosocialquality of life

Identifiers

PMID29802810
PMCPMC6378691
OpenAlexW2804008952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.